|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/4965 | |
| A61K 31/497 | |||
| C07D 403/12 | |||
| A61P 35/00 |
| (11) | Patento numeris | 3104860 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15746362.1 |
| Europos patento paraiškos padavimo data | 2015-02-09 | |
| (97) | Europos patento paraiškos paskelbimo data | 2016-12-21 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-12-30 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2015/015030 |
| Data | 2015-02-09 |
| (87) | Numeris | WO 2015/120390 |
| Data | 2015-08-13 |
| (30) | Numeris | Data | Šalis |
| 201402277 | 2014-02-10 | GB | |
| 201462083687 P | 2014-11-24 | US |
| (72) |
BOYLE, Robert George, GB
WALKER, David Winter, GB
BOYCE, Richard Justin, GB
PETERSON, Scott, US
FAROUZ, Francine, US
VO, Cong Hung, US
|
| (73) |
Sentinel Oncology Limited,
181 Science Park Milton Road, Cambridge Cambridgeshire CB4 0GJ,
GB
|
| (54) | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS |
| PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS |